COMMITMENTS AND CONTINGENCIES (Details) $ in Thousands |
12 Months Ended | |
|---|---|---|
|
Feb. 04, 2022
item
|
Dec. 31, 2025
USD ($)
|
|
| Columbia License Agreement | ||
| COMMITMENTS AND CONTINGENCIES | ||
| Number of times license agreement has been amended | item | 5 | |
| Extension period | 6 months | |
| Aggregate amount obligated to pay on achieving specified development and regulatory approval milestones | $ 20,000 | |
| Aggregate amount obligated to pay on achieving on achieving a specified cumulative sales milestone | 25,000 | |
| Payments made | 4,000 | |
| Additional payment obligation | 6,000 | |
| Clinical Research Organization (CRO) | ||
| COMMITMENTS AND CONTINGENCIES | ||
| Remaining contractual costs expected to be incurred in future periods from clinical trials in STGD1 | $ 31,894 |